SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 8-K
Document Type: EX-99.1
Date Filed: 2026-05-14
Accession Number: 0001213900-26-056244
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026056244/ea029076501ex99-1.htm

Chunk 0 of 2
Word Count: 1499
Character Count: 10082

Document Content:

Exhibit 99.1

Synergy CHC Corp. Reports First Quarter 2026
Financial Results

N. WINDHAM, Maine, May 14, 2026 –
Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, is announcing
its financial results for the three months ended March 31, 2026.

“Our first quarter results reflect continued
execution and the growing momentum of our functional beverage business,” said Jack Ross, CEO of Synergy CHC Corp. “During
the quarter, we generated over $650,000 in functional beverage revenue, exceeding our total beverage revenue for all of 2025. This performance
reflects the success of our expanding retail and distribution partnerships across the U.S., supported by healthy sell-through that is
already driving increased reorder activity. Reflecting this momentum, our beverage division is operating at an estimated annual run rate
exceeding $4 million. With this foundation in place and continued expansion of our distribution footprint underway, we believe we are
well-positioned to capture the significant growth opportunities emerging within the functional beverage sector. With solid early-year
momentum and a clear strategic path, we expect 2026 to be a year of sustainable growth and value creation for our shareholders.”

First Quarter 2026 Financial Summary vs. Same
Year-Ago Period

●	Revenue of $5.49 million vs. $8.17 million.

●	Gross margin of 72.3% vs. 75.4%.

●	Income (loss) from operations of ($0.57) million
vs. $1.95 million.

●	Net income (loss) of ($2.57) million vs. $0.88
million.

●	Earnings (loss) per share of ($0.23) vs. $0.10.

●	EBITDA (loss), a non-GAAP financial measure,
was ($0.54) million vs. $1.98 million.

●	Adjusted EBITDA (loss), a non-GAAP financial
measure, was ($0.35) million vs. $1.98 million.

First Quarter 2026 Financial Results

Revenue in the first quarter of 2026 was $5.49
million compared to $8.17 million in the first quarter of 2025, due to license revenue of $1.5 million in 2025 that did not repeat in
2026 and out-of-stock dynamics for several key online items in our Flat Tummy brand, which impacted online sales. This was partially offset
by strong performance in beverages, which delivered significantly higher revenue compared to the prior year period.

Gross margin in the first quarter of 2026 was
72.3% compared to 75.4% in the first quarter of 2025. Excluding license revenue from the first quarter of 2025, normalized gross margin
for that period was 70.0%, a 2.3% improvement year-over-year.

Operating expenses in the first quarter of 2026
were $4.54 million compared to $4.22 million in the first quarter of 2025, reflecting higher overhead associated with the expansion of
the beverage business.

Income (loss) from operations for the first quarter
of 2026 was ($0.57) million compared to $1.95 million in the first quarter of 2025, which is largely due to the license revenue of $1.5
million in 2025 that did not repeat in 2026 and increased overhead costs.

Net income (loss) in the first quarter of 2026
was ($2.57) million compared to net income of $0.88 million in the first quarter of 2025.

Earnings (loss) per share in the first quarter
of 2026 was ($0.23) compared to $0.10 in the first quarter of 2025.

EBITDA (loss) (a non-GAAP financial measure) in
the first quarter of 2026 was ($0.54) million compared to $1.98 million in the first quarter of 2025.

Adjusted EBITDA (loss) (a non-GAAP financial measure)
in the first quarter of 2026 was ($0.35) million compared to $1.98 million in the first quarter of 2025.

Balance Sheet and Cash Flow

As of March 31, 2026, Synergy had approximately
$0.30 million in cash and cash equivalents, compared to $2.6 million in cash and cash equivalents as of December 31, 2025. Subsequent
to quarter-end, Synergy raised approximately $2.7 million in gross proceeds through its at-the-market (ATM) equity offering program.

As of March 31, 2026, Synergy had a working capital
deficit of $0.50 million, compared to a $1.78 million working capital surplus as of December 31, 2025.

As of March 31, 2026, Synergy had $3.4 million
in inventory, compared to $3.7 million in inventory as of December 31, 2025.

Cash used in operating activities for the three
months ended March 31, 2026 was $2.0 million compared to cash used in operating activities of $0.82 million for the three months ended
March 31, 2025.

Non-GAAP Financial Measure Reconciliation:
EBITDA and Adjusted EBITDA

To assist financial statement users in an assessment
of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and
related events, as the Company believes that the non-GAAP information enhances investors’ overall understanding of our financial performance,
and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

Management believes EBITDA and Adjusted EBITDA
provide useful information to investors by excluding certain items that may not be indicative of the Company’s core operating results
and that can vary significantly between periods. EBITDA is defined as net income plus interest expense, income tax expense, depreciation
and amortization. Adjusted EBITDA is calculated as EBITDA plus or minus foreign exchange gains or losses, one-time expenses and non-cash
expenses. Since Adjusted EBITDA is a non-GAAP financial performance measure, the Company’s calculation of Adjusted EBITDA may not
be comparable to other similarly titled measures of other companies; and should not be considered in isolation, as a substitute for, or
superior to measures of financial performance prepared in accordance with GAAP.

The following table reconciles net income to EBITDA
and Adjusted EBITDA (in millions of US dollars):

3 Months ended March 31

Net (loss) income for the period $	(2.57	) $	0.88

Adjusted for:

Interest expense, net 2.01 1.08

Amortization of intangible assets 0.03 0.03

Tax benefit (0.01	) (0.01	)

EBITDA $	(0.54	) $	1.98

Foreign currency adjustment (0.00	) 0.00

Stock based compensation 0.16 -

Board expenses 0.03 -

Adjusted EBITDA $	(0.35	) $	1.98

About Synergy CHC Corp.

Synergy CHC Corp. develops and markets consumer
health and wellness products, led by its flagship brands FOCUSfactor® and Flat Tummy®. FOCUSfactor®,
a clinically studied brain health supplement and functional beverage line with a 25-year legacy, enjoys established distribution in the
U.S., Canada and Mexico, through major retailers including Costco, Walmart, Amazon, BJ’s, and Walgreens, among others. Flat Tummy® complements
Synergy’s portfolio as a lifestyle brand focused on women’s wellness and weight management.

Forward Looking Statements

Certain statements contained in this press
release constitute “forward-looking statements,” including statements regarding brand expansion and growth initiatives. These
forward-looking statements represent Synergy’s expectations or beliefs concerning future events, and it is possible that the results described
in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which
are set forth in Synergy’s registration statement on Form S-1, as amended, many of which are outside of Synergy’s control, that could
cause actual results to differ materially from the results discussed in the forward-looking statements.

Any forward-looking statement speaks only as
of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible
for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and
other cautionary statements in Synergy’s filings with the SEC. The risk factors and other factors noted in Synergy’s filings could
cause its actual results to differ materially from those contained in any forward-looking statement.

Investor Relations

Gateway Group

Cody Slach, Greg Robles

SNYR@gateway-grp.com

Synergy CHC Corp.

Condensed Consolidated Balance Sheets

March 31,
2026 December 31,

(unaudited)

Assets

Current Assets

Cash and cash equivalents $	292,115 $	2,622,313

Restricted cash 100,000 100,000

Accounts receivable, net 1,268,022 3,203,505

Prepaid expenses (including related party amount of $652,270 and $110,803, respectively) 1,303,173 351,049

Inventory, net 3,381,614 3,737,509

Total Current Assets 6,344,924 10,014,376

Intangible assets, net 116,667 150,000

Total Assets $	6,461,591 $	10,164,376

Liabilities and Stockholders’ Deficit

Current Liabilities:

Accounts payable and accrued liabilities (including payable to shareholder of $193,641 and $197,512, respectively) $	4,031,994 $	6,388,219

Income taxes payable 85,811 88,108

Contract liabilities - 1,526

Short term loans payable, net of debt discount, related party - 100,000

Current portion of notes payable, net of debt discount 2,730,981 1,658,215

Total Current Liabilities 6,848,786 8,236,068

Long-term Liabilities:

Notes payable, net of debt discount 25,018,055 25,056,446

Total long-term liabilities 25,018,055 25,056,446

Total Liabilities 31,866,841 33,292,514

Commitments and contingencies

Stockholders’ Deficit:

Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 shares issued; 11,303,853 outstanding 114 114

Additional paid in capital 33,710,857 33,594,550

Common stock to be issued 153,400 -

Accumulated other comprehensive loss (132,201	) (154,281	)

Accumulated deficit (59,009,920	) (56,441,021	)

Less: Treasury stock (180,073 shares) at cost (127,500	) (127,500	)

Total stockholders’ deficit (25,405,250	) (23,128,138	)

Total Liabilities and Stockholders’ Deficit $	6,461,591 $	10,164,376

Synergy CHC Corp.

Unaudited Condensed Consolidated Statements of
Operations and Comprehensive (Loss) Income

For the three months ended For the three months ended